Progress in clinical neurosciences: The 'antiplatelet' agents and the role of the endothelium

Canadian Journal of Neurological Sciences

Volumn 34, Issue 3, 2007, Pages 270-279

  Mateen, Farrah J ^a,c   Shuaib, Ashfaq ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLIC AMP; CYCLIC GMP; DIPYRIDAMOLE; NAPROXEN; PLACEBO; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; TRAPIDIL;

ANTIINFLAMMATORY ACTIVITY; ARTERY STEAL SYNDROME; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INFORMATION RETRIEVAL; LEUKOCYTE FUNCTION; LOW DRUG DOSE; MEDLINE; MONOTHERAPY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOGENICITY; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VASCULAR PATENCY; VASODILATATION;

EID: 34548407690     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100006685     Document Type: Review

References (122)

1. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet. 1997;349:1391-2.
2. Vane JR, Änggård EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27-36.
3. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998;97:716-20.
4. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation. 1997;96:3042-7.
5. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109 Suppl II:II-27-33.
6. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy M, Simonson DC, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97:1695-1701.
7. Noon JP, Walker BR, Malcolm FH, Webb DJ. Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin. Cardiovasc Res. 1998;38:480-4.
8. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. 2000;102:994-9.
9. Visseren F, Bouter K, Bouwman J, Erkelens D, Diepersloot R. Procoagulant activity of endothelial cells after infection with respiratory viruses. Eur J Clin Invest. 1996;26:A8 (abstr.)
10. Valtonen V, Kuikka A, Syrjanen J. Thrombo-embolic complications in bacteraemic infections. Eur Heart J. 1993;14 Suppl K:20-3.
11. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6.
12. Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol. 1992;69:1596-601.
13. Weiss HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet. 1967;2:295-7.
14. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-18.
15. Hankey GJ, Eikelboom JW. Antiplatelet drugs. Med J Aust. 2003;178, 568-74.
16. Müller TH. Inhibition of thrombus formation by low-dose acetylsalicylic acid, dipyridamole, and their combination in a model of platelet-vessel wall interaction. Neurology. 2001;57 Suppl 2:S8-S11.
17. Catella-Lawson F. Vascular biology of thrombosis platelet-vessel wall interactions and aspirin effects. Neurology. 2001;57 Suppl 2:S5-S7.
18. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-9.
19. Torsney E, Mayr U, Zou Y, Thompson WD, Hu Y, Xu Q. Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. Circ Res. 2004;94:1466-73.
20. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-4.
21. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/Iiz antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003;107:1123-8.
22. Mach F, Schönbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-Cd40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA. 1997;94:1931-6.
23. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-8.
24. Schönbeck U, Libby. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-1103.
25. Aguejouf O, Belougne-Malfatti E, Doutremepuich F, Belon P, Doutremepuich C. Thromboembolic complications several days after a single dose administration of aspirin. Thromb Res. 1998;89:12-7.
26. Nishimura H, Naritomi H, Iwamoto Y, Tachibana H, Sugita M. In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. Stroke. 1996;27:1099-104.
27. Eldor A, Vlodavsky I, Fuks Z, Muller TH, Eisert WG. Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells. Thromb Haemost. 1986;56:333-9.
28. Aguejouf O, Malfatti E, Belon P, Doutremepuich C. Time related neutralization of two doses acetyl salicylic acid. Thromb Res. 2000;100:317-23.
29. Bhagat K, Collier J, Vallance P. Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection to infarction? Cardiovasc Res. 1996;32:822-9.
30. Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, MacAllister RJ, et al. Prevention of inflammation-induced endothelial dysfunction: a new vasculo-protective action of aspirin. Circulation. 2002;105:2600-4.
31. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639-46.
32. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and the low-dose aspirin in healthy subjects. Circulation. 2004;109:1468-71.
33. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118:503-8.
34. Liu Y, Pelekanakis K, Woolkalis MJ. Thromin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun. J Biol Chem. 2004; 279:3512-7.
35. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng J Med. 1990;323:236-41.
36. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation. 1995; 91:1914-7.
37. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-72.
38. Biasucci LM, Liuzzo G, Fantuzzi, Galigiuri G, Rebuzzi AG, Ginnetti F, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99:2079-84.
39. Lopez-Farre A, Caramelo C, Esteban A, Alberola ML, Millás I, Montón M, et al. Myocardial ischemia/myocardial infarction: effects of aspirin on platelet-neutrophil interactions: role of nitric oxide and endothelin-1. Circulation. 1995;91;2080-8.
40. Li N, Wallén NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation. 1999;100:1374-9.
41. Evangelista V, Manarini S, Sideri R, Rotondo S, Martelli N, Piccoli A, et al. Platelet/polymorphonuclear leukocyte interaction : P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood. 1999;93:876-85.
42. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Coronary heart disease/myocardial infarction/bypass grafts/endothelial function: increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 1996;94:1239-46.
43. Asako H, Kubes P, Wallace J, Wolf RE, Granger DN. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology. 1992;103:146-52.
44. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhnesion. Proc Natl Acad Sci U S A. 1991;88:4651-5.
45. Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leukocyte ativation as monitored by whole blood flow cytometry. Thromb Res. 2003;111,165-70.
46. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human cute myocardial infarction. Circulation. 2001;104:1533-7.
47. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, et al. Circulating monocyte-platelet aggregates are an early markder of acute myocardial infarction. J Am Coll Cardiol. 2001;38:1002-6.
48. Mickelson JK, Ali MN, Kleiman NS, Lakkis NM, Chow TW, Hughes BJ, et al. Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol. 1999;33:97-106.
49. Serebruany VL, Malinin AI, Ziai W, Pokov AN, Bhatt DL, Alberts MJ, et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke. Stroke 2005;36:2289-92.
50. Lancelot E, Callebert J, Revaud M, Boulu RG, Plotkine M. Detection of hydroxyl radicals in rat striatum during transient focal cerebral ischemia: possible impolication in tissue damage. Neurosci Lett. 1995;85-8.
51. Kuhn W, Muller T, Buttner T, Gerlach M. Aspirin as a free radical scavenger: consequences for therapy of cerebrovascular ischemia. Stroke. 1995;26:1959-60.
52. Kukreja RC, Kontos HA, Hess ML, Ellis EF. PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH. Circ Res. 1986;59:612-9.
53. Armstead WM, Mirro R, Busija DW, Leffler CW. Postischemic generation of superoxide anion by newborn pig brain. Am J Physiol. 1998;255:H401-3.
54. Sagone AL, Husney RM. Oxidation of salicylates by stimulated granulocytes: evidence that these drugs act as free radical scavengers in biological systems. J Immunol. 1987;138:2177-83.
55. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344:793-5.
56. Steer KA, Wallace TM, Bolton CH, Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart. 1997;77:333-7.
57. Eisele G, Schwedhelm E, Schieffer B, Tsikas D, Böger RH. Acetyl salicylic acid inhibits monocyte adhesion to endothelial cells by an antioxidative mechanism. J Cardiovasc Pharmacol. 2004;43:514-21.
58. Barbato JE, Tzeng E. Nitric oxide and arterial disease. J Vasc Surg. 2004;40:187-93.
59. Madajka M, Korda M, White J, Malinski T. Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO. Thromb Res. 2003;110:317-21.
60. Taubert D, Berkels R, Grosser N, Schroder H, Grundemann D, Schomig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol. 2004;143:159-65.
61. Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282-91.
62. Dupin JP, Gryglewski RJ, Gravier D, Hou G, Casadebaig F, Swies J, et al. Synthesis and thrombolytic activity of new thienopyrimidinone derivatives. J Physiol Pharmacol. 2002;53:625-34.
63. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100:1667-72.
64. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin I patients at risk of ischaemic events (CAPRIE). Lancet. 1996;100:1667-72.
65. Gachet C, Stierle A, Cazenave JP, Ohlmann P, Lanza F, Bouloux C, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb/IIIa complex in rat and in man. Biochem Pharmacol. 1990;40:229.
66. Gryglewski RJ, Korbut R, Âwi's J, Kostka-Tràbka E, Bierof K, Robak J. Thrombolytic action of ticlopidine: possible mechanisms. Eur J Pharmacol. 1996;308:61-7.
67. Harker LA. Therapeutic inhibition of platelet function in stroke. Cerebrovasc Dis. 1998;8 Suppl 5:8-18.
68. Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am Heart J. 2000;140:67-73.
69. Müller I, Seyfarth M, Rüdiger S, Wolf B, Pogatsa-Murray G, Schömig A, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001; 85:92-3.
70. Arrebola MM, De La Cruz JP, Villalobos MA, Pinacho A, Guerrero A, Sánchez de la Cuesta F. In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J Cardiovasc Pharmacol. 2004;43:74-82.
71. Gryglewski RJ, Uracz W, Âwi's J. Unusual effects of aspirin on ticlopidine induced thrombolysis. Thorax. 2000;55 Suppl 2:S17-9.
72. de Lorgeril M, Bordet JC, Salen P, Durbin S, Defreyn G, Delaye J, et al. Ticlopidine increases nitric oxide generation in heart-transplant recipients: a possible novel property of ticlopidine. J Cardiovasc Pharmacol. 1998;32:225-30.
73. Yao S, Ober JC, Ferguson JJ, Maffrand J, Anderson HV, Buja M, et al. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol. 1994;267:H488-93.
74. Savi P, Bernat A, Dumas A, Aït-Chek L, Herbert J. Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells. Thromb Res. 1994;73:117-24.
75. Kleiman NS. Platelets, the cardiologist, and coronary artery disease: moving beyond aggregation. J Am Coll Cardiol. 2004; 43:1989-91.
76. Yao S, Ober JC, NcNatt J, Benedict CR, Rosolowsky M, Anderson HV, et al. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res. 1992;70:39-48.
77. Anderson HV, McNatt J, Clubb FJ, Herman M, Maffrand J, DeClerck F, et al. Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries. Circulation. 2001;104:2331-7.
78. Kornowski R, Mintz GS, Kent KM, Pitchard AD, Satler LF, Buchar TA, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. Circulation. 1997;95:1366-9.
79. Mudra H, Regar E, Klauss V, Werner F, Henneke KH, Sbarouni E, et al. Serial follow-up after optimized ultrasound-guided deployment of Palmaz-Shatz stents: in stent neointimal proliferation without significant reference segment response. Circulation. 1997;95:363-70.
80. Yao S, McNatt J, Kexin C, Vernon H, Maffrand J, Buja LM, et al. Endothelial function/myocardial ischemia/infarction: combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed nad endothelium-injured arteries in nonhuman primates. Circulation. 1993;88:2888-93.
81. Folts JD, Rowe GG. Epinephrine potentiation of in vivo stimuli reverse aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries. Thromb Res. 1998;50:507-16.
82. Gurbel PA, Bliden KP, Hiatt BL, O'Conner CM. Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-13.
83. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol. 2004;93:456-8.
84. Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets. 2004;15:95-9.
85. Payne DA, Jones CI, Hayes PD, Thompson MM, London NJ, Bell PR, et al. Beneficial effects of clopidogrel combined with aspirin in reducing cerbral emboli in patients undergoing carotid endarterectomy. Circulation. 2004;109:1476-81.
86. Escolar G, Bastida E, Castillo R, Ordinas A. Ticlopidine inhibits platelet thrombus formation studied in a flowing system. Thromb Res. 1987;45:561-71.
87. Vivekananthan DP, Bhatt DL, Chew DP, Zidar FJ, Chan AW, Moliterno DJ, et al Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol. 2004;94:358-60.
88. Chew DP, Bhatt DL, Robbins MA, Mukherjee D, Roffi M, Schneider JP, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001;88:672-4.
89. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001;104:163-7.
90. Xiao Z, Théroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol. 2004;43:1982-8.
91. Gurbel PA, Malinin AI, Callahan KP, Serebruany VL, O'Connor CM. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. Am J Cardiol. 2002;90:312-5.
92. Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther. 2002;71:176-85.
93. Gibbs CR, Lip GY. Do we still need dipyridamole? Br J Clin Pharmacol. 1998;45:323-8.
94. Moncada S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet. 1978;1:1286-9.
95. Bult H, Fret HR, Jordaens FH, Herman AG. Dipyridamole potentiates platelet inhibition by nitric oxide. Thromb Heamost. 1991;66:343-9.
96. Kjaer A, Meyer C, Nielsen FS, Parving H, Hesse B. Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes. J Nuc Med. 2003;44:19-23.
97. Lupi A, Buffon A, Finocchiaro ML, Conti E, Maseri A, Crea F. Mechanisms of adenosine-induced epicardial coronary artery dilatation. Eur Heart J. 1997;18:614-7.
98. Gamboa A, Ertl AC, Costa F, Farley G, Manier ML, Hachey DL, et al. Blockade of nucleoside transport is required for delivery of intraarterial adenosine into the interstitium. Circulation. 2003;108:2631-5.
99. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Neurol Sci. 1996; 143:1-13.
100. FitzGerald GA. Dipyridamole. N Engl J Med. 1987;316:1247-56.
101. Liem LK, Choong LH, Woo KT. Action of dipyridamole and warfarin on growth of human endothelial cells cultured in serum-free media. Clin Biochem. 2001;34:141-7.
102. Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res. Suppl 1983;4:39-46.
103. Nishimura H, Naritomi H, Iwamoto Y, Tachibana H, Sugita M. In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. Stroke. 1996;27:1099-103.
104. Aktas B, Utz A, Hoenig-Liedl P, Walter U, Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets in vitro and in vivo/ex vivo studies. Stroke. 2003;34:764-9.
105. Eisert WG. Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology. 2001;57 Suppl 2:S20-3.
106. Guideri F, Capecchi PL, Acampa M, Cuomo A, Lazzerini PE, De Giorgi L, et al. Oral low-dose dipyridamole protects from intravenous high-dose dipyridamole-induced ischemia. A stress echocardiographic study. Int J Cardiol. 2002;83:209-16.
107. Suzuki K, Miura T, Miki T, Tsuchida A, Shimamoto K. Infarct-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: evidence for the role of interstitial adenosine level during precondition as a primary determinant of cardioprotection. J Cardiovasc Pharmacol. 1998;31:1-9.
108. Klabunde RE. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol. 1983;93:21-6.
109. Bijlstra P, van Ginneken EE, Huls M, van Dijk R, Smits P, Rongen GA. Glyburide inhibits dipyridamole-induced forearm vasodilation but not adenosine-induced forearm vasodilation. Clin Pharmacol Ther. 2004;75:147-56.
110. Abd-Elfattah AS, Hoehner J, Wechsler AS. Identification of nucleoside transport binding sites in the human myocardium. Mol Cell Biochem. 1998;180:105-10.
111. Nees S, Herzog V, Becker BF, Bock M, Des Rosiers C, Gerlach E. The coronary endothelium: a highly active metabolic barrier for adenosine. Basic Res Cardiol. 1985; 80:515-29.
112. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, Spencer ED, Dixon DA, Marathe GK, et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation. 2005; 111; 633-42.
113. Howell JG, Zibari GB, Brown MF, Burney DL, Sawaya DE, Olinde JG, et al. Both ischemic and pharmacological preconditioning decrease hepatic leukocyte/endothelial cell interactions. Transplantation. 2000;69:300-3.
114. Bouma MG, van den Wildenberg FA, Buurman WA. The anti-inflammatory potential of adenosine in ischemia-reperfusion injury: established and putative beneficial actions of a retaliatory metabolite. Shock. 1997;8:313-20.
115. Grisham MB, Hernandez LA, Granger DN. Adenosine inhibits ischemia-reperfusion-induced leukocyte adherence and extravasation. Am J Physiol. 1989;257(5 Pt 2):H1334-9.
116. Iuliano L, Pedersen JZ, Rotilio G, Ferro D, Violi F. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Rad Biol Med. 1995;18:239-47.
117. Iuliano L, Colavita AR, Camastra C, Bello V, Quintarelli C, Alessandroni M, et al. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol. 1996;119:1438-46.
118. Nozik-Grayck E, Piantadosi CA, van Adelsberg J, Alper SL, Huang YT. Protection of perfused lung from oxidant injury by inhibitors of anion exchange. Am J Physiol. 1997;273(2 Pt 1):L296-304.
119. Blake AD. Dipyridamole is neuroprotective for cultured rat embryonic cortical neurons. Biochem Biophys Res Comm. 2004;314:501-4.
120. Kim JA, Tran ND, Zhou W, Fisher M. Dipyridamole enhances tissue plasminogen activator release by brain capillary endothelial cells. Thromb Res. 2004;115:435-8.
121. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
122. ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006;367:1665-73.